BackCytoMed Therapeutics Overview

CytoMed Therapeutics Total Liabilities

Track CytoMed Therapeutics's total liabilities ($1.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$1.13M
↑ 50.72% YoYΔ $380693.00 vs prior year quarter

Peer trimmed avg / median

Loading

CytoMed Therapeutics Total Liabilities History

Loading

CytoMed Therapeutics vs. peers: Total Liabilities Comparison

Loading

CytoMed Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CytoMed Therapeutics (GDTC) FAQ

CytoMed Therapeutics (GDTC) currently reports a total liabilities of $1.1M as of December 2025. That compares with $750K in the prior-year period — up 50.7% year over year. Use the charts on this page to explore CytoMed Therapeutics's total liabilities history and peer comparisons.

CytoMed Therapeutics's total liabilities increased from $750K to $1.1M — a 50.7% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytoMed Therapeutics reported $1.1M in total liabilities as of December 2025. That compares with $750K in the prior-year period — up 50.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $1.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CytoMed Therapeutics, and consider following GDTC for alerts when major investors trade the stock.